Literature DB >> 18085467

The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.

Elizabeth D Sharpe1, Adam C Reynolds, Gregory L Skuta, Jessica N Jenkins, William C Stewart.   

Abstract

PURPOSE: To evaluate the incidence and characteristics of periocular pigmentation with latanoprost versus bimatoprost.
METHODS: A retrospective, active-controlled comparison of consecutive patients treated with latanoprost or bimatoprost for 12 months evaluating patients to determine the incidence, characteristics, and reversibility of periocular pigmentation.
RESULTS: Periocular pigmentation was found in 1% patients treated with latanoprost and 6% patients treated with bimatoprost within 12 months of beginning treatment (p = 0.004).
CONCLUSIONS: This study suggests that periocular pigmentation may develop after treatment with latanoprost or bimatoprost.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18085467     DOI: 10.1080/02713680701750625

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  7 in total

1.  Adverse periocular reactions to five types of prostaglandin analogs.

Authors:  K Inoue; M Shiokawa; R Higa; M Sugahara; T Soga; M Wakakura; G Tomita
Journal:  Eye (Lond)       Date:  2012-10-05       Impact factor: 3.775

Review 2.  Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 3.  In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma.

Authors:  Silvio DI Staso; Luca Agnifili; Sara Cecannecchia; Angela DI Gregorio; Marco Ciancaglini
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

4.  Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension.

Authors:  Kenji Inoue; Minako Shiokawa; Michitaka Sugahara; Risako Higa; Masato Wakakura; Goji Tomita
Journal:  Clin Ophthalmol       Date:  2012-01-12

Review 5.  Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.

Authors:  Daniel Lee; Anand V Mantravadi; Jonathan S Myers
Journal:  Clin Ophthalmol       Date:  2017-07-10

6.  Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.

Authors:  Saki Fukaya; Masahiro Kamata; Tomoko Kasanuki; Makoto Yokobori; Shintaro Takeoka; Kotaro Hayashi; Takamitsu Tanaka; Atsuko Fukuyasu; Takeko Ishikawa; Takamitsu Ohnishi; Satoshi Iimuro; Yayoi Tada; Shinichi Watanabe
Journal:  J Dermatol       Date:  2018-08-29       Impact factor: 4.005

Review 7.  Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog.

Authors:  Yoshimi Niwano; Atsuo Iwasawa; Masahiko Ayaki
Journal:  Ophthalmol Eye Dis       Date:  2014-02-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.